Metabolic adaptations underlie epigenetic vulnerabilities in chemoresistant breast cancer. [RNA-Seq2]

Purpose:Assess the difference in gene expression of taxol-resistant TNBC cells relative to parental cells (MDA-MB-436 and HS 578t) Methods: RNA-seq was performed on paclitaxel-treated MDA-MB-436 cells that are resistant to Paclitaxel (R20A, R20B, R20C) and in control-treated (DMSO) parental MDA-MB-436 cells that are sensitive to Paclitaxel (DMSO) Results: We mapped about 20 million sequence reads per sample to the human genome (hg19) and identified identified differentially expressed genes Conclusions: Our study identified genes significantly enriched or repressed in taxol-resistant cells relative to parental cells in both TNBC models (MDA_MB-436 and HS 578T) Overall design: RNA-seq was performed on paclitaxel-treated MDA-MB-436 cells that are resistant to Paclitaxel (R20A, R20B, R20C) and in control-treated (DMSO) parental MDA-MB-436 cells that are sensitive to Paclitaxel (DMSO)

研究目的：评估紫杉醇耐药三阴性乳腺癌（Triple-Negative Breast Cancer, TNBC）细胞相较于亲本细胞（MDA-MB-436与HS 578t）的基因表达差异。实验方法：采用RNA测序（RNA-seq）技术，对经紫杉醇处理的紫杉醇耐药MDA-MB-436细胞（R20A、R20B、R20C）以及经对照处理（二甲基亚砜，DMSO）的紫杉醇敏感亲本MDA-MB-436细胞进行测序。实验结果：我们将每个样本约2000万条序列读数比对至人类基因组（hg19），并鉴定出差异表达基因。研究结论：本研究在两种三阴性乳腺癌模型（MDA-MB-436与HS 578T）中，均鉴定出相较于亲本细胞显著富集或表达抑制的紫杉醇耐药相关基因。整体实验设计：采用RNA测序（RNA-seq）技术，对经紫杉醇处理的紫杉醇耐药MDA-MB-436细胞（R20A、R20B、R20C）以及经对照处理（二甲基亚砜，DMSO）的紫杉醇敏感亲本MDA-MB-436细胞进行测序。